Biocatalysts, a global biotechnology company, has announced it has been named as one of the winners of the Queen’s Awards for Enterprise in Innovation.
In an April 23, 2019 press release, Biocatalysts, a global biotechnology company, has announced it has been named as one of the winners of the Queen’s Awards for Enterprise in Innovation.
The Queen’s Awards for Enterprise are announced annually and are granted to United Kingdom businesses deemed to have demonstrated ‘outstanding achievement’ in the fields of innovation, international trade, sustainable development, and promoting opportunity through social mobility.
Biocatalysts has been granted an award in recognition of its approach to providing enzyme solutions to its customers. Specifically, the company has been recognized for its MetXtra bespoke software system, which is capable of screening millions of sequences to identify new enzymes in hours.
Rod Sears-Black, Biocatalysts’ managing director, commented in the release, “We are very proud to receive the Queen’s award for Innovation. It recognizes the dedication and commitment of the Biocatalysts team to create this unique offering to the market.”
Source: Biocatalysts
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.